Organization
LungenClinic Grosshansdorf, German Center for Lung Research
3 abstracts
Abstract
IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).Org: Tongji University Affiliated Shanghai Pulmonary Hospital, Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int., Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, MI Zaporizhzhia Regional Clinical Oncological Dispensary Zaporizhzhia SMU Ch of Oncology, LKI Lungenfachklinik Immenhausen,
Abstract
Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.Org: Northwestern University Feinberg School of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Regional and Virgen de la Victoria University Hospitals, IBIMA, Hospital Clínic de Barcelona, IDIBAPS,
Abstract
Early detection of lung cancer using small RNAs.Org: Hummingbird Diagnostics, Klinikverbund Allgäu, Klinikum Konstanz, Translational Lung Research Center Heidelberg, University Hospital Essen,